Texas Oncology - Central South

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Bladder cancer1 trial
• Cervical cancer1 trial
• Endometrial cancer1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 1/22 trials
• Phase 32 trials
• Phase 21 trial
• Phase 41 trial

Status

• Recruiting5 trials
• Completed1 trial

Lead sponsor

• Pfizer5 trials
• Xencor, Inc.1 trial

Running trials

• Recruiting

  Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

  NCT07578649· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

  NCT06952660· Phase 4· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT05005728· Phase 2· Xencor, Inc.· Source